Anthracycline associated cardiotoxicity in survivors of childhood cancer.
about
Cardiotoxicity in childhood cancer survivors: strategies for prevention and managementThe tell-tale heart: molecular and cellular responses to childhood anthracycline exposureCurrent Views on Anthracycline Cardiotoxicity in Childhood Cancer SurvivorsIs it possible to cure childhood acute myeloid leukaemia without significant cardiotoxicity?Mechanisms of anthracycline cardiotoxicity and strategies to decrease cardiac damage.Evaluation of traditional and novel measures of cardiac function to detect anthracycline-induced cardiotoxicity in survivors of childhood cancer.Risk and associated risk factors of hospitalization for specific health problems over time in childhood cancer survivors: a medical record linkage studyCost-effectiveness of the children's oncology group long-term follow-up screening guidelines for childhood cancer survivors at risk for treatment-related heart failure.VHL deficiency augments anthracycline sensitivity of clear cell renal cell carcinomas by down-regulating ALDH2.Pregnancy in a patient with cancer and heart failure: challenges and complexities.Clinical research directions in pediatric cardiology.AAML0523: a report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia.Cardiovascular disease in adult survivors of childhood cancer.P53 inhibition exacerbates late-stage anthracycline cardiotoxicity.Cardiac status of children infected with human immunodeficiency virus who are receiving long-term combination antiretroviral therapy: results from the Adolescent Master Protocol of the Multicenter Pediatric HIV/AIDS Cohort Study.Potential genetic predisposition for anthracycline-associated cardiomyopathy in families with dilated cardiomyopathy.Astragalus polysaccharide suppresses doxorubicin-induced cardiotoxicity by regulating the PI3k/Akt and p38MAPK pathways.Anthracycline cardiotoxicity: from bench to bedside.Cardiovascular effects in childhood cancer survivors treated with anthracyclines.Anthracycline-associated cardiotoxicity in survivors of childhood cancer.Changes in echocardiographic measures of systolic and diastolic function in children 1 year after hematopoietic SCTPlasma high sensitivity troponin T levels in adult survivors of childhood leukaemias: determinants and associations with cardiac function.Adverse effects of treatment in childhood acute lymphoblastic leukemia: general overview and implications for long-term cardiac health.Pretreatment with angiotensin-converting enzyme inhibitor improves doxorubicin-induced cardiomyopathy via preservation of mitochondrial function.Anthracycline treatment and ventricular remodeling in left ventricular assist device patients.Role of genetic susceptibility in development of treatment-related adverse outcomes in cancer survivors2010 Riley Heart Center Symposium on Cardiac Development: cardiomyocyte injury and protectionNT-proBNP as early marker of subclinical late cardiotoxicity after doxorubicin therapy and mediastinal irradiation in childhood cancer survivorsManaging chemotherapy-related cardiotoxicity in survivors of childhood cancers.Apoptosis in Anthracycline CardiomyopathyPhysical activity among adult survivors of childhood lower-extremity sarcoma.Late cardiotoxicity after low dose of anthracycline therapy for acute lymphoblastic leukemia in childhood.Impact of Cancer Therapy-Related Exposures on Late Mortality in Childhood Cancer Survivors.Anthracycline-Related Cardiotoxicity in Patients with Acute Myeloid Leukemia and Down Syndrome: A Literature ReviewChanges in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomesCardiovascular status of childhood cancer survivors exposed and unexposed to cardiotoxic therapy.A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer.Doxorubicin-induced cardiomyopathy 17 years after chemotherapyRationale and design of the Children's Oncology Group (COG) study ALTE1621: a randomized, placebo-controlled trial to determine if low-dose carvedilol can prevent anthracycline-related left ventricular remodeling in childhood cancer survivors at higStrategies to prevent anthracycline-related congestive heart failure in survivors of childhood cancer.
P2860
Q24628695-9482A5A5-CF98-4BB3-A967-228D54792E5FQ26823592-35087BEF-D411-475B-92CC-56D93A07B929Q28083073-B34CB7C1-8CF1-4ABF-8CC6-B33195BA7E7DQ30244600-5829DABB-2AEF-46BB-92BD-B0092E3FCE9BQ30439608-EC593F64-5AEB-45E6-A6C9-C546AF75F653Q33590755-F50E40CD-92F4-4F09-81D4-17CB72F9B870Q33679623-DC0203FD-109F-4229-A753-FF84ED0BA901Q33815037-41F30122-6968-409F-BA26-0056AB34CE5BQ33826897-BB6D4F90-E265-427B-9F71-A99383741EADQ33885550-B9B3198C-D2DD-47CC-BCEF-561170B5D952Q33944043-E94DEF5A-4D62-4C46-B34D-66FFDD93810BQ34021009-47278D44-0AB0-4D23-A7B2-F05CE76868B8Q34042984-8F8DC9B1-3072-4182-B369-9CAE0DA4BBD3Q34048273-83B96EA1-294D-49A9-89E2-32A12257DBDAQ34269964-4C42EC3B-01F5-4DFE-8D76-C8E766B929FCQ34333236-3D47C33A-E346-4466-BE22-1AC33DAB3204Q34438288-B6E7106F-BF51-4E27-AA66-3F0F08420095Q34477415-6EF98A9D-CE95-4C64-8B26-9AED8DFF79ACQ34572109-71209D9E-80C0-4567-B92F-90A930404214Q34626238-153718CC-1E1A-476E-B7DD-1B67FCFBD274Q35019395-3EBCBCB5-8F1F-492C-919D-0639594C5B2CQ35034995-4B6CC8D4-5132-4533-88B1-6A9485F27F8FQ35076156-E4E7578E-43AB-4A1C-9377-73C4E9DD4F3AQ35214168-FF66863A-9F4C-40C2-A79B-B508EC161BF5Q35246219-CF044B13-D47B-4252-9663-1CA003414F01Q35327266-C59FB66A-30E5-406F-B638-8BA396DC2C20Q35414698-A1BDDBC5-375D-489E-A390-1DE3A652B6C9Q35557142-C42E17DE-7141-4CBE-84F6-EE2222E43C7AQ35562745-C28666C2-437D-4644-899A-B884C1F912D4Q35642302-B3EE1EEF-B280-49C4-905A-DDA703E9B9C7Q35643218-9A612E73-E8B6-4ED8-96C5-1E83AF8D8D66Q35757419-B6E5FAE5-4082-4CDE-8AC5-E93412CD5AB5Q35761588-D71C83E1-464A-4AD9-A6F0-6BDADACB7ABDQ35888110-1A040CEC-13B1-4690-AAE7-D1EDA779DA1EQ35925266-AD5474A1-DD35-4FFD-969C-F41253933242Q35925270-90E63BC3-5B13-4C10-B375-E1F9E4149508Q36004460-3C49AE90-B3A2-40CC-8BA5-0E02B3FB3040Q36011893-384AD016-BEFB-41F3-9695-2C6F76BD7299Q36156912-0F0BEC81-DCBC-4DA8-A1FD-406C9859F5CCQ36184665-CDB4B0F5-6AEF-4262-81D8-F2E0B1BA9815
P2860
Anthracycline associated cardiotoxicity in survivors of childhood cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Anthracycline associated cardiotoxicity in survivors of childhood cancer.
@en
Anthracycline associated cardiotoxicity in survivors of childhood cancer.
@nl
type
label
Anthracycline associated cardiotoxicity in survivors of childhood cancer.
@en
Anthracycline associated cardiotoxicity in survivors of childhood cancer.
@nl
prefLabel
Anthracycline associated cardiotoxicity in survivors of childhood cancer.
@en
Anthracycline associated cardiotoxicity in survivors of childhood cancer.
@nl
P356
P1433
P1476
Anthracycline associated cardiotoxicity in survivors of childhood cancer.
@en
P2093
Jorge A Alvarez
Rebecca E Scully
P304
P356
10.1136/HRT.2007.136093
P407
P577
2008-04-01T00:00:00Z